Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Gross Margin for 8 consecutive years, with 97.82% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 70.0% year-over-year to 97.82%, compared with a TTM value of 98.18% through Dec 2025, down 38.0%, and an annual FY2025 reading of 98.18%, down 38.0% over the prior year.
  • Gross Margin was 97.82% for Q4 2025 at Neurocrine Biosciences, roughly flat from 98.24% in the prior quarter.
  • Across five years, Gross Margin topped out at 98.77% in Q1 2021 and bottomed at 79.33% in Q2 2021.
  • Average Gross Margin over 4 years is 96.93%, with a median of 98.39% recorded in 2025.
  • The sharpest move saw Gross Margin tumbled -1987bps in 2021, then soared 57bps in 2024.
  • Year by year, Gross Margin stood at 98.58% in 2021, then dropped by 0bps to 98.35% in 2023, then rose by 0bps to 98.52% in 2024, then dropped by -1bps to 97.82% in 2025.
  • Business Quant data shows Gross Margin for NBIX at 97.82% in Q4 2025, 98.24% in Q3 2025, and 98.36% in Q2 2025.